Krishnan Chakravarthy
Pain Medicine · Temecula, CANPI 1043573488
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $795,832 of the $1,262,057 with a category attached, or 63.1%. Medtronic accounts for 69.4% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2022 at $287,876 and has fallen 77.9% since, to $63,532 in 2025. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,069 payments — averaging $609.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$876K
- Abbott$173K
- MML US, Inc.$144K
- Vertos Medical, Inc.$29K
- Bioness Inc$15K
- Boston Scientific$6K
- plus $19K from 27 others
Across 93 payments — averaging $7637.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mesoblast, Inc.$431K
- MML US, Inc.$132K
- Medtronic$63K
- Abbott$41K
- Bioventus LLC$38K
- Vertos Medical, Inc.$5K
- plus $62 from 1 others
What the payments were for
- Consulting fees$257,37920%
- Speaking & faculty fees$795,83263%
- Travel & lodging$139,90211%
- Food & beverage$52,5354%
- Education$15,2981%
- Entertainment$1950%
- Ownership interest$9170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 1,199 | $876,486 |
| Abbott | 386 | $172,541 |
| MML US, Inc. | 142 | $143,898 |
| Vertos Medical, Inc. | 41 | $28,890 |
| Bioness Inc | 3 | $15,195 |
| Boston Scientific | 104 | $6,373 |
| Stryker | 2 | $3,063 |
| Omnia Medical, LLC | 2 | $3,000 |
| Nalu Medical, Inc. | 32 | $2,400 |
| Bioventus LLC | 1 | $1,600 |
| Si-bone, Inc. | 13 | $1,208 |
| Painteq LLC | 16 | $1,182 |
| Nevro Corp. | 27 | $957 |
| Vertiflex, Inc. | 7 | $940 |
| Spinal Simplicity, LLC | 12 | $683 |
| Stimwave Technologies Incorporated | 7 | $595 |
| Tersera Therapeutics LLC | 15 | $511 |
| Relievant Medsystems, Inc. | 8 | $466 |
| Saluda Medical Americas, Inc. | 12 | $448 |
| SPR Therapeutics, Inc | 11 | $402 |
| Biotronik NRO, Inc. | 2 | $302 |
| Avanos Medical | 7 | $223 |
| Mesoblast, Inc. | 1 | $178 |
| Curonix LLC | 4 | $162 |
| Curiteva, Inc. | 1 | $126 |
| Collegium Pharmaceutical, Inc. | 7 | $120 |
| Neuronetics, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Tenex Health Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$435,379
- INTELLIS$195,934
- ReActiv8$142,247
- Neuromodulation Dspsbls and Accs$86,842
- VANTA ADAPTIVESTIM$58,849
- Proclaim Family of SCS IPGs$58,559
- RESTORE$41,829
- mild Device Kit$31,287
- Stimrouter for pain$15,195
- Neuromodulation-Research Only$13,145
- SYNCHROMEDII$7,981
- Vanta$6,880
- Prodigy Family of SCS IPGs$5,670
- ADAPTIVESTIM$4,725
- SYNCHROMED$4,442
- NVISION$3,000
- Inflate FX$2,500
- SUPERION$1,753
- Intracept$1,745
- Stimrouter Implantable Kit$1,600
How this compares
$1,262,057 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 44 | $1,322 |
| Oxycodone Hcl | 18 | $299 |
| Meloxicam | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Temecula
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
- Einar OttestadStanford$352K
- Shveta JainFullerton$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.